[go: up one dir, main page]

WO2013043703A1 - Recueil de tissus graisseux par liquéfaction tissulaire - Google Patents

Recueil de tissus graisseux par liquéfaction tissulaire Download PDF

Info

Publication number
WO2013043703A1
WO2013043703A1 PCT/US2012/056088 US2012056088W WO2013043703A1 WO 2013043703 A1 WO2013043703 A1 WO 2013043703A1 US 2012056088 W US2012056088 W US 2012056088W WO 2013043703 A1 WO2013043703 A1 WO 2013043703A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
interior cavity
fat
tissue
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/056088
Other languages
English (en)
Inventor
Mark S. Andrew
Phillip P. Chan
Christopher P. Godek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrew Technologies LLC
Original Assignee
Andrew Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrew Technologies LLC filed Critical Andrew Technologies LLC
Priority to CA2849081A priority Critical patent/CA2849081A1/fr
Publication of WO2013043703A1 publication Critical patent/WO2013043703A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/320016—Endoscopic cutting instruments, e.g. arthroscopes, resectoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3203—Fluid jet cutting instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3203—Fluid jet cutting instruments
    • A61B17/32037—Fluid jet cutting instruments for removing obstructions from inner organs or blood vessels, e.g. for atherectomy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00274—Prostate operation, e.g. prostatectomy, turp, bhp treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00743—Type of operation; Specification of treatment sites
    • A61B2017/00792—Plastic surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00743—Type of operation; Specification of treatment sites
    • A61B2017/00796—Breast surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00969—Surgical instruments, devices or methods used for transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22079—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for with suction of debris
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22081—Treatment of vulnerable plaque
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
    • A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
    • A61B2018/00029—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids open
    • A61B2018/00035—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids open with return means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00339—Spine, e.g. intervertebral disc
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2217/00—General characteristics of surgical instruments
    • A61B2217/002—Auxiliary appliance
    • A61B2217/005—Auxiliary appliance with suction drainage system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/71—Suction drainage systems
    • A61M1/77—Suction-irrigation systems
    • A61M1/774—Handpieces specially adapted for providing suction as well as irrigation, either simultaneously or independently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/84—Drainage tubes; Aspiration tips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0014—Special media to be introduced, removed or treated removed from the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/08—Lipoids

Definitions

  • the Coleman approach fat tissue is extracted from a source location (e.g., the buttocks) using a syringe. The tissue that is extracted is then centrifuged for a specified length of time at particular settings. After centrifuging, the high density portion is on the bottom and the low density portion is on top. The high density portion of the centrifuged matter is then selected (e.g. by skimming off the top one third or top one half and discarding the skimmed-off portion).
  • a source location e.g., the buttocks
  • the high density portion of the centrifuged matter is then selected (e.g. by skimming off the top one third or top one half and discarding the skimmed-off portion).
  • the high density portion is then injected into the target site (e.g. a breast).
  • the Coleman approach has a number of disadvantages, including the fact that it is difficult to obtain a large volume of tissue rapidly.
  • Other possible sources of fat include fat that is obtained by a conventional liposuction technique e.g., Suction Assisted Lipoplasty ("SAL”) or Vaser-Ultrasonic Assisted Lipoplasty (“V-UAL"). But the fat that is obtained using these liposuction procedures is not ideal for reintroduction to the patient's body due to low-viability issues and other problems.
  • SAL Suction Assisted Lipoplasty
  • V-UAL Vaser-Ultrasonic Assisted Lipoplasty
  • stem cell isolation it may be desirable to harvest adipose stem cells from a patient's body for subsequent use. This is sometimes referred to as stem cell isolation.
  • One conventional approach for isolating stem cells is to start with a lipoaspirate from a conventional liposuction technique (e.g., SAL or V-UAL).
  • the lipoaspirate is first gravity- separated into a supranatant (which contains mostly fat) and an infranatant (which contains mostly blood and fluids that were injected during the liposuction).
  • the supranatant is then treated with the collagenase to separate the cells from each other.
  • the supranatant is centrifuged, which separates the supranatant into three layers: a second generation supranatant on top, an infranatant beneath the supranatant, and a stromal vascular fraction ("SVF") beneath the infranatant.
  • the SVF contains adipose stem cells which can then be used for all permitted purposes. But this approach is problematic because it requires collagenase, which can be difficult to remove, and can be very dangerous.
  • portions of fatty tissue are drawn into orifices in a cannula, and a heated solution is impinged against those portions of tissue.
  • the heated solution liquefies or gellifies parts of the fatty tissue, so they can be removed from the patient's body more easily.
  • the fat that is so removed is better suited for reintroduction into a patient's body as compared to fat that is harvested using other approaches.
  • the fat that is removes using the methods and apparatuses described herein can also be used as a raw material for stem cell isolation, without relying on the use of collagenase.
  • [0005] 1 shows an embodiment of a tissue liquefaction system.
  • FIG. 2 is a detail of the distal end of the FIG. 1 embodiment.
  • FIG. 3 is a section view of alternative configuration for the distal end of the
  • FIG. 1 embodiment.
  • FIG. 4 is a detail of another alternative configuration for the distal end of the
  • FIG. 1 embodiment.
  • FIGS. 5 and 5 A show another embodiment of a tissue liquefaction system, which includes a forward-facing external tumescent spray applicator.
  • FIG. 6 shows some variations of the distal end of the cannula.
  • FIG. 7 shows how the cannula can be configured with external fluid-supply paths, in less preferred embodiments.
  • FIG. 8 shows how the cannula can be configured with the fluid supply paths internal to the suction path.
  • FIG. 9 shows a cannula with a single fluid supply tube internal to the suction path
  • FIG. 10 shows a cannula configuration with two internal fluid supply tubes.
  • FIG. 11 shows a cannula having two fluid supply paths internal to the suction path.
  • FIG. 12 shows a cannula with six fluid supply paths internal to the suction path.
  • FIG. 13 shows an alternative cannula configuration with six internal fluid supply paths.
  • FIG. 14 is a block diagram of a suitable fluid heating and pressurization system
  • FIG. 15 shows a high speed camera fluid supply image and pressure rise graph.
  • the embodiments described below generally involve the delivery of pressurized heated biocompatible fluid to heat targeted tissue and soften, gellify, or liquefy the target tissue for removal from a living body.
  • the heated biocompatible fluid is preferably delivered as a series of pulses, but in alternative embodiments may be delivered as a continuous stream. After the tissue has been softened, gellified, or liquefied, it is sucked away out of the subject's body.
  • the interaction with the subject takes place at a cannula 30, examples of which are depicted in FIGS. 1-4.
  • the distal end of cannula is preferably smooth and rounded for introduction into the subject's body, and the proximal end of the cannula is configured to mate with a handpiece 20.
  • the cannula 30 has an interior cavity with one or more orifice ports 37 that open into the cavity. These orifices 37 are preferably located near the distal portion of the cannula 30. When a low pressure source is connected up to the cavity via a suitable fitting, suction is generated which draws target tissue into the orifice ports 37.
  • the cannula also includes one or more fluid supply tubes 35 that direct the heated fluid onto the target tissue that has been drawn into the cavity.
  • These fluid supply tubes are preferably arranged internally to the outside wall of the cannula (as shown in FIG. 8), but in alternative embodiments may be external to the cannula for a portion of the length of the supply tube (as shown in FIG. 7).
  • the heated fluid supply tubes 35 preferably terminate within the outside wall of the cannula, in the vicinity of the suction orifice ports 37.
  • the fluid supply tubes 35 are arranged to spray the fluid across the orifice ports 37 so that the fluid strikes the target tissue that has been drawn into the cavity. Delivery of the tissue fluid stream is preferably contained within the outer wall of the cannula.
  • the fluid delivery portion may be implemented using a fluid supply reservoir
  • a heat source 8 that heats the fluid in the reservoir 4
  • a temperature regulator 9 that controls the heat source 8 as required to maintain the desired temperature.
  • the heated fluid from the fluid supply 4 is delivered under pressure by a suitable arrangement such as a pump system 19 with a pressure regulator 11.
  • a heated f uid metering device 12 may also be provided to measure the fluid that has been delivered.
  • Pump 19 pumps the heated fluid from the reservoir or f uid supply source 4 down the f uid supply tubes 35 that run from the proximal end of the cannula 30 down to the distal end of the cannula.
  • these fluid supply tubes preferably make a U-turn so as to face back towards the proximal end of the cannula 30.
  • the pump delivers a pressurized, pulsating output of heated fluid down the supply tube 35 so that a series of boluses of fluid are ejected from the delivery orifice 43, as described in greater detail below.
  • the vacuum source and the fluid source interface with the cannula 30 via a handpiece 20.
  • the heated solution supply is connected on the proximal side of hand piece 20 with a suitable fitting, and a vacuum supply is also connected to the proximal side of handpiece 20 with a suitable fitting.
  • Cannula 30 is connected to the distal side of hand piece 20 with suitable fittings so that (a) the heated fluid from the fluid supply is routed to the supply tubes 35 in the cannula and (b) the vacuum is routed from the vacuum source 14 to the cavity in the cannula, to evacuate material from the cavity.
  • the pressurized heated solution that is discharged from pump 19 is connected to the proximal end of the handle 20 via high pressure flexible tubing, and routed through the handpiece 20 to the cannula 30 with an interface made using an appropriate fitting.
  • the vacuum source 14 is connected to an aspiration collection canister 15, which in turn is connected to the proximal end of the handle via flexible tubing 16 or other fluid coupling, and then routed through the handpiece 20 to the cannula 30 with an interface made using an appropriate fitting.
  • the aspiration collection canister 15, and the flexible tubing 16 are preferably sterile, and optionally disposable.
  • a cooling system may be added to cool the matter that is suctioned into the collection container in order to extend the life of the fat cells.
  • the cooling may take place using any conventional approach while the aspirated material is in the tubing on its way into the collection canister 15, or alternatively in the collection canister itself.
  • a wide variety of cooling systems may be used, including but not limited to compressor / evaporator based systems, Peltier based systems, and ice or cold water-jacket based systems.
  • the degree of cooling is preferably not so severe so as to cause the aspirate to coagulate in the tubing.
  • the pressurized fluid supply line connection between the handle and the cannula 30 may be implemented using a high pressure quick disconnect fitting located at the distal end of the handle, and configured so that once the cannula is inserted into the distal end of the handle it aligns and connects with both the fluid supply and the vacuum supply.
  • the cannula 30 may be held in place on the handle 20 by an attachment cap.
  • vacuum source 14 creates a low pressure region within cannula 30 such that the target fatty tissue is drawn into the cannula 30 through suction orifice 37.
  • the geometry of the end of the supply tube 35 is configured so the trajectory of the boluses leaving the delivery orifice will strike the fatty tissue that has been drawn into the cannula 30 through suction orifice 37.
  • the end of the supply tube preferably points in direction that is substantially parallel to that of the inside wall of the cannula 30 where it is affixed. Preferably, it is oriented that the stream flows across the orifice in a distal to proximal direction.
  • This placement of the tip 43 of the supply tube 35 advantageously maximizes the energy transfer (kinetic and thermal) to the fatty tissues, minimizes fluid loss, and helps prevent clogs by pushing the heated fluid and the liquefied/gellified/softened material in the same direction that it is being pulled by the vacuum source.
  • the targeted fatty tissue enters the suction orifice 37, it is repeatedly struck by the boluses of heated fluid that are exiting the supply tubes 35 via the delivery orifice 43.
  • the target fatty tissue is heated by the impinging boluses of fluid and is softened, gellified, or liquefied. After that occurs, the loose material in the cavity (i.e., the heated fluid and the portions of tissue that were dislodged by the fluid) is drawn away from the surrounding tissue by the vacuum source 14, and is deposited into the canister 15 (shown in FIG. 1).
  • fat is more readily softened, gellified, or liquefied (as compared to other types of tissue), so the process targets subcutaneous fat more than other types of tissue.
  • distal-to-proximal direction of the boluses is the same as the direction that the liquefied/gellified tissue travels when it is being suctioned out of the patient via the cannula 30.
  • additional energy vacuum, fluid thermal and kinetic
  • This further contributes to reducing clogs, which can reduce the time it takes to perform a procedure.
  • the majority of the fluid stays within the interior of the cannula during operation (although a small amount of fluid may escape into the subject's body through the suction orifices 37).
  • This is advantageous because minimizing fluid leakage from the cannula into the tissue maximizes the energy transfer (thermal and kinetic) from the fluid stream to the tissue drawn into the cannula for liquefaction.
  • FIG. 3 depicts a cut-away view of an embodiment of the cannula 30 that has two supply tubes 35.
  • Each of the supply tubes 35 is provided for delivering the heated fluid.
  • Supply tube 35 extends from the proximal portion of cannula 30 to the distal tip 32 of cannula 30.
  • Supply tube 35 extends along the interior of cannula 35 and may be a separate structure secured to the interior of cannula 35 or lumen integrated into the wall of cannula 30.
  • Supply tube 35 is configured to deliver heated biocompatible solution for liquefying tissue. The heated solution is delivered through hand piece 20 and into supply tube 35.
  • the supply tube 35 extends longitudinally along axis 33 from the proximal end 31 to the distal tip 32.
  • Supply tube 35 includes U-bend 41 , effectively turning the run of the supply tube 35 along the inner wall of the distal tip 32.
  • Adjacent the terminal end of u- bend 41 is supply tube terminal portion 42, which includes delivery orifice 43.
  • Delivery orifice 43 is configured to direct heated solution exiting supply tube 35 across suction orifice port 37. In this manner, supply tube 35 is configured to direct the fluid onto a target tissue that has entered the cannula 30 through the suction orifice port 37.
  • Heated solution supply tube 35 may be constructed of surgical grade tubing.
  • the supply tube 35 may be made of the same material as cannula 30.
  • the diameter of supply tube 35 may be dependent on the target tissue volume requirements for the heated solution and on the number of supply tubes required to deliver the heated solution across the one or more suction orifice ports 37.
  • the cannula 30 tube diameters vary with the cannula outside diameters and those can range from 2-6 mm.
  • the fluid supply tube 35 diameters are dependent on the inside diameters of the tubes. A preferred range of supply tube 35 diameters is from about 0.008" to 0.032".
  • the supply tube 35 is a 0.02" diameter for the length of the cannula 30, with an exit nozzle formed by reducing the diameter to 0.008" over the last 0.1".
  • the shape and size of delivery orifice 43 may vary, including reduced diameter and flattened configurations, with the reduced diameter being preferred.
  • the cannula 30 may have a different number of heated solution supply tubes 35, each corresponding to a respective suction orifice port.
  • a cannula 30 with three suction orifice ports 37 would preferably include three heated solution supply tubes 35.
  • heated solution supply tubes may be added to accommodate one or more suction orifice ports, e.g., when four suction orifice ports are provided, four heated solution supply tubes may be provided.
  • a supply tube 35 may branch into multiple tubes, each branch servicing a suction orifice port.
  • one or more supply tubes may deliver the heated fluid to a single orifice port.
  • supply tube 35 may be configured to receive one or more fluids in the proximal portion of cannula 30 and deliver the one or more fluids though a single delivery orifice 43.
  • the cannula may be attached to an endoscope or other imaging device.
  • cannula 30 may include a forward-facing external fluid delivery applicator 45 in addition to the distal-to-proximal fluid supply tube 35.
  • the heated fluid should be biocompatible, and may comprise a sterile physiological serum, saline solution, glucose solution, Ringer-lactate, hydroxyl-ethyl-starch, or a mixture of these solutions.
  • the heated biocompatible solution may comprise a tumescent solution.
  • the tumescent solution may comprise a mixture of one or more products producing different effects, such as a local anesthetic, a vasoconstrictor, and a disaggregating product.
  • the biocompatible solution may include xylocaine, marcaine, nesacaine, Novocain, diprivan, ketalar, or lidocaine as the anesthetic agent.
  • Epinephrine, levorphonal, phenylephrine, athyl-adrianol, or ephedrine may be used as vasoconstrictors.
  • the heated biocompatible fluid may also comprise saline or sterile water or may be comprised solely of saline or sterile water.
  • FIG. 14 depicts one example of a suitable way to heat the fluid and deliver it under pressure.
  • the components in FIG. 14 operate using the following steps: Room temperature saline drains from the IV bag 51 into mixing storage reservoir 54. Once the fluid in the reservoir 54 reaches a fixed limit, the fixed speed peristaltic pump 55 of the heater system 8 moves fluid from the reservoir 54 to the heater bladder 56. The fluid is circulated through the bladder and is heated by the electric panels 57 of the heater system 8. The heated fluid is returned back to the reservoir 54 and mixes with the other fluid in the storage container. The fixed speed peristaltic pump 55 continues to circulate fluid to the heater unit and back into the reservoir 54. The continuous circulation of fluid provides a very stable and uniform heated fluid volume supply.
  • Temperature control may be implemented using any conventional technique, which will be readily apparent to persons skilled in the relevant arts, such as a thermostat or a temperature-sensing integrated circuit.
  • the temperature may be set to a desired level by any suitable user interface, such as a dial or a digital control, the design of which will also be apparent to persons skilled in the relevant arts.
  • the pump 58 may be a piston-type pump that draws heated fluid from the fluid reservoir 54 into the pump chamber when the pump plunger travels in a backstroke.
  • the fluid inlet to the pump has an in-line one-way check valve that allows fluid to be suctioned into the pump chamber, but will not allow fluid to flow out.
  • displacement pump is to use an off-set cam on the pump motor that causes the pump shaft to travel in a linear motion.
  • the pump shaft is loaded with an internal spring that maintains constant tension against the off-set cam.
  • a one-way check valve is located at the inlet port to the pump chamber, which allows fluid to flow into the chamber on the backstroke and shuts once the fluid is pressurized on the forward stroke. Multiple inlet ports can allow for either heated or cooled solutions to be used.
  • the heated fluid is pressurized to a preset pressure (e.g. 1100 psi) in the pump chamber, which causes the valve on the discharge port to open, discharging the pressurized contents of the pump chamber to fluid supply tubes 35.
  • a preset pressure e.g. 1100 psi
  • the pressure in the pump chamber decreases and the discharge valve closes.
  • the pump shaft can be made with a cut relief, which will allow the user to vary the boluses size. The cut off on the shaft will allow for all the fluid in the pumping chamber to be ported through the discharge path to the supply tubes or a portion of the pressurized fluid to be ported back to the reservoir.
  • the heated biocompatible solution in a tissue liquefaction system is preferably delivered in a manner optimized for softening, gellifying, or liquefying the target tissue.
  • Variable parameters include, without limitation, the temperature of the solution, the pressure of the solution, the pulse rate or frequency of the solution, and the duty cycle of the pulses or boluses within a stream.
  • the vacuum pressure applied to the cannula through vacuum source 14 may be optimized for the target tissue.
  • the biocompatible heated solution should preferably be delivered to the target fatty tissue at a temperature between 75 and 250 degrees F, and more preferably between 110 and 140 degrees F.
  • a particular preferred operating temperature for the heated solution is about 120 degrees F, since this temperature appears very effective and safe.
  • the pressure of the heated solution is preferably between about 200 and about 2500 psi, more preferably between about 600 and about 1300 psi, and still more preferably between about 900 and about 1300 psi.
  • a particular preferred operating pressure is about 1100 psi, which provides the desired kinetic energy while minimizing fluid flow.
  • the pulse rate of the solution is preferably between 20 and 150 pulses per second, more preferably between 25 and 60 pulses per second. In some embodiments, a pulse rate of about 40 pulses per second was used.
  • the heated solution may have a duty cycle (i.e., the duration of the pulses divided by the period at which the pulses are delivered) of between 1-100%. In preferred embodiments, the duty cycle may range between 30 and 60%, and more particularly between 30 and 50%>.
  • the rise rate (i.e., the speed with which the fluid is brought to the desired pressure) is about 1 millisecond or faster. This may be accomplished by having a standard relief valve that opens once the pressure in the pump chamber reaches the set point (which, for example, may be set to 1100 psi). As shown in FIG. 15, the pressure increase is almost instantaneous, as evidenced by the spike representing the rise rate in the pressure rise graph (inset). FIG. 15 further illustrates how the fluid exits the fluid supply tubes during a very short time span.
  • FIG. 3 depicts an expanded cut-away view of an embodiment that includes two suction orifices.
  • the cannula 30 has two suction orifices 37 located near the distal region of the cannula 30 and proximal to distal tip 32.
  • Suction orifice ports 37 may be positioned in various configurations about the perimeter of the distal region of cannula 30. In the illustrated embodiment, the suction orifice ports 37 are on opposite sides of tile cannula 30, but in alternative embodiments they may be positioned differently with respect to each other. Suction orifice ports 37 are configured to allow fatty tissue to enter the orifices in response to low pressure within the cannula shaft created by vacuum supply 14.
  • the material that is located in the cavity i.e., tissue that has been dislodged and the heated fluid that exited the supply tube 35
  • a conventional vacuum pump e.g., the AP-III HK Aspiration Pump from HK surgical
  • the vacuum level may be adjustable by the operator during the procedure. Because reduced aspiration vacuum is expected to lower blood loss, operator may prefer to work at the lower end of the vacuum range.
  • the aspiration vacuum preferably ranges from 300-700 mm Hg.
  • Exceeding 700 mm Hg is not recommended during fat harvesting because it can have an adverse impact on the viability of the fat cells that are harvested.
  • Hand piece 20 has a proximal end 21 and a distal end 22, a fluid supply connection 23 and a vacuum supply connection 24 preferably located at the proximal end, and a fluid supply fitting and a vacuum supply fitting at the distal end (to interface with the cannula).
  • the hand piece 20 routes the heated fluid from the fluid supply to the supply tubes 35 in the cannula and routes the vacuum from the vacuum source 14 to the cavity in the cannula, to evacuate material from the cavity.
  • a cooling fluid supply 6 may be used to dampen the heat effect of the heated fluid stream in the surgical field.
  • the handpiece also routes the cooling fluid into the cannula 35 using appropriate fittings at each end of the handpiece.
  • a cooling fluid metering device 13 may optionally be included.
  • the hand piece 20 may optionally include operational and ergonomic features such as a molded grip, vacuum supply on/off control, heat source on/off control, alternate cooling fluid on/off control, metering device on/off control, and fluid pressure control. Hand piece 20 may also optionally include operational indicators including cannula suction orifice location indicators, temperature and pressure indicators, as well as indicators for delivered fluid volume, aspirated fluid volume, and volume of tissue removed.
  • one or more of the aforementioned controls may be placed on a separate control panel.
  • the distal end 22 of hand piece 20 is configured to mate with the cannula 30.
  • Cannula 30 comprises a hollow tube of surgical grade material, such as stainless steel, that extends from a proximal end 31 and terminates in a rounded tip at a distal end 32.
  • the proximal end 31 of the cannula 30 attaches to the distal end 22 of hand piece 20. Attachment may be by means of threaded screw fittings, snap fittings, quick-release fittings, factional fittings, or any other attachment connection known in the art. It will be appreciated that the attachment connection should prevent dislocation of cannula 30 from hand piece 20 during use, and in particular should prevent unnecessary movement between cannula 30 and hand piece 20 as the surgeon moves the cannula hand piece assembly in a back and forth motion approximately parallel to the cannula longitudinal axis 33.
  • the cannula may include designs of various diameters, lengths, curvatures, and angulations to allow the surgeon anatomic accuracy based upon the part of the body being treated, the amount of fat extracted as well as the overall patient shape and morphology.
  • the cannula may be a solid cylindrical tube, articulated, or flexible.
  • Each of the suction orifice ports 37 includes a proximal end 38, a distal end
  • suction orifice port perimeter 40 may be oval or round, in alternative embodiments they may be made in other shapes (e.g., egg shaped, diamond or polygonal shaped, or an amorphous shape).
  • the suction orifice ports 37 may be arranged in a linear fashion on one or more sides of cannula 30. Alternatively, the suction orifice ports 37 may be provided in a multiple linear arrangement, as depicted in FIG. 4.
  • the dimensions or shape of each suction orifice port may change, for example, from the most distal suction orifice port to the most proximal, as illustrated in FIG. 4, where the diameter of each suction orifice port may decrease in succession from the distal port to the proximal port.
  • the suction orifice perimeter edge 40 is configured to present a smooth, unsharpened edge to discourage shearing, tearing or cutting of the target fatty tissue. Because the target tissue is liquefied/gellified/softened; the cannula 30 does not need to shear tissue as much as found in traditional liposuction cannulas. In these embodiments, the perimeter edge 40 is duller and thicker than typically found in prior-art liposuction cannulas. In alternative embodiments, the cannula may use shearing suction orifices, or a combination of reduced-shearing and shearing suction orifice ports. The suction orifice port perimeter edge 40 of any individualized suction orifice port may also be configured to include a shearing surface or a combination of shearing and reduced -shearing surfaces, as appropriate for the particular application.
  • FIG. 6 shows some exemplary suction orifices of different size.
  • Cross section F is shown with a standard shearing orifice port 37.
  • Cross section G has a larger shearing orifice port 37, while cross section H has a perimeter with a smooth and unsharpened edge to discourage shearing.
  • the long axis should preferably be oriented substantially parallel to the distal -to-proximal axis.
  • the suction orifices should not be too large, because with smaller suction orifices less fat is suctioned into the cannula for a given bolus of energy. On the other hand they should not be too small, to permit the fatty tissue to enter.
  • a suitable size range for circular suction orifices is between about 0.04" and 0.2".
  • a suitable side for oblong suction orifices is between about 0.2" x 0.05" and about 1 ⁇ 2" x 1 ⁇ 2".
  • the size of the suction orifices can further be varied for different applications depending on the surgeon's requirements. More extensive areas to be suctioned may require larger orifices which require more shearing surface.
  • the surface area of a unit length of the suction path can be calculated by multiplying the total perimeter of the suction path by a unit length.
  • An exemplary perimeter of the suction path is ⁇ (4.115 mm), which when multiplied by 1 mm length, gives a unit length area of 12.9 mm .
  • FIG. 7 shows the diameter of the inside of the suction path (which would then be multiplied by ⁇ to give the perimeter length and then by a unit length of 1 mm to give the surface area of 12.93).
  • FIG. 7 shows the diameter of the inside of the suction path (which would then be multiplied by ⁇ to give the perimeter length and then by a unit length of 1 mm to give the surface area of 12.93).
  • the calculated resistance ratio of the suction path is 1.68 and the calculated resistance ratio of the fluid path (both tubes included) is 4.92. Accordingly, the comparative resistance ratio is 0.38.
  • the suction resistance ratio is 1.1 1 and the fluid resistance ratio 4.61 , so the comparative resistance ratio is 0.24.
  • the suction resistance ratio is 1.20 and the fluid resistance ratio 5.98, so the comparative resistance ratio equals 0.20.
  • the suction resistance ratio is 1.31 and the fluid resistance ratio is 4.65, so the comparative resistance ratio is 0.28.
  • the suction resistance ratio is 2.25 and the fluid resistance ratio 7.88, so the comparative resistance ratio is 0.29.
  • the suction resistance ratio is 1.23 and the fluid resistance ratio is 10.23, so the comparative resistance ratio is 0.12.
  • adipocytes viable fat cells
  • adipocytes viable fat cells
  • a similar method may be used to address post liposuction depressions and/or concavities from over aggressive liposuction.
  • Other procedures utilizing a similar method include; without limitation, breast augmentation, breast lifts, breast reconstruction, general plastic surgery reconstruction, facial reconstruction, reconstruction of the trunk and/or extremities.
  • Adipose tissue cell viability of four different fat harvesting modalities was compared by analyzing fresh tissue samples taken from one live human subject using all four different modalities.
  • the four fat harvesting modalities were: (1) using the embodiments and methods described above (referred to herein as "Andrew” Lipoplasty, based on the name of the inventor of this application); (2) using a Coleman syringe ("CS”); (3) using standard Suction Assisted Lipoplasty (“SAL”); and (4) using Vaser-Ultrasonic Assisted Lipoplasty (“V-UAL”). Four samples from the Andrew modality and one sample from each of the other modalities were analyzed, making a total of seven samples.
  • the testing was performed under expert guidance, directed by a world authority on adipose tissue cell biology. A total of four PhDs in cell biology were present. Tissue sample preparation of all four fat harvesting modalities was identical, using standard centrifugation and collagenase protocols. The steps that were implemented are described below.
  • the waste containers containing the fat aspirates were brought from the third floor operating suite to the first floor lab.
  • the material in the containers was already settling into an obvious supranatant layer (an upper layer) consisting of mainly fat tissue, and an infranatant layer (a lower layer) consisting mainly of a fluidic mixture of blood and/or saline.
  • the difference between the Andrew containers and all the other containers was obvious and marked: the Andrew supranatant was light yellow in color, was clearly a homogeneous liquid, was devoid of chunks of connective tissue ("CT") and clumps of fat tissue, and was devoid of blood - there was no hint of redness whatsoever.
  • CT connective tissue
  • the Andrew infranatant was a thin, light salmon/pink colored liquid. All other non-Andrew lipo waste containers looked similar: the supranatant was reddish- orange in color and clearly contained blood, the SAL and V-UAL supranatants were not homogeneous liquids and contained obvious chunks of CT tissue and clumps of fat, the Coleman supranatant appeared thick and clumpy and was not a homogeneous liquid (but definitive appearing chunks of connective tissue were not discernible), and all the non- Andrew infranatants appeared to be a dark red, thick, blood-like fluid. The seven aspirate samples arrived in the lab sequentially, at 15 -20 minute intervals from one to the next. As the samples arrived they were allowed to settle for a few minutes.
  • the first analysis that was done was to determine whether the lipoasprirate was in a state of cell suspension.
  • samples of the Coleman and Andrew supranatants (#1) were taken using a pipette and exposed to trypan blue stain. The stained samples were then placed on a hemocytometer cell counting slide and viewed under the microscope. Microscopically, the Andrew supranatant was observed to be in a state of cell suspension, and was observed to be almost a single cell suspension. (It was believed by all cell biologists present that the #1 Andrew sample could be gotten to a single cell suspension by diluting it.) The Coleman sample was in clumps and was not in a cell suspension state.
  • the Vision Cell Analyzer distinguishes adipocytes from lipid droplets; the fluorescent dyes stain only cells and not lipid droplets.
  • the first dye stains all cells present, alive, and dead cells.
  • the second dye stains only dead cells.
  • the automated cell counter counts all cells present and can distinguish between live and dead cells.
  • the software in the Vision Cell Analyzer does a subtraction and gives you the percentage of live cells present. Four separate fields are read and averaged. The results for the four different modalities are tabulated on Table 1 below. All the samples were prepared identically (i.e., all were post centrifugation and post collagenase digestion). Note that four different samples using the Andrew modality were tested (at various temperature and pressure settings and two different anatomical locations).
  • the size of the cell clumps in that suspension has a significant effect on how well the cells will take in their transplanted location. It turns out that the cells take better when the cells are in smaller clumps (as compared to cells that are in larger clumps). But the clumps should also not be too small.
  • the Andrew, SAL, and V-UAL systems all remove tissue from a patient's body relatively quickly, but the Coleman approach is comparatively slow.
  • the fat extracted using the Andrew system is in a cell suspension state with relatively small clump size; the fat extracted using the Coleman approach ends up in clumps of fat that are not in a cell suspension state; and the matter extracted using SAL and UAL was not in a cell suspension state at all.
  • Fat that is in a cell suspension state with relatively small clump size is ideal for reintroduction into a target site in the patient's body, and the Andrew system is the only approach that provides rapid extraction of fat tissue that is in a cell suspension state with relatively small clump size.
  • the Andrew approach is therefore superior to the other three approaches in this regard. [0068] Another reason why the Andrew approach is superior to the other three approaches is because the cell viability is highest using the Andrew approach, as shown in the data presented above.
  • the lipoaspirate from the UAL and SAL approaches contain a significant amount of blood in other undesirable components.
  • the Andrew lipoaspirate will probably not need washing before it can be introduced into the patient's body (or, at the very least, will require less washing as compared to the other approaches).
  • the Andrew approach is superior to the other approaches.
  • the Andrew lipoaspirate had a smoother consistency (possibly due to the fact that the Andrew lipoaspirate is in a cell suspension state with a relatively small clump size), and can therefore be pushed out of the injection syringe using lower pressure.
  • the fat cells in the Coleman approach was not as smooth (possibly due to the larger clump size) and would require a higher injection pressure to push out of the injection syringe. Since higher pressure can damage the fat being injected, the Andrew approach is superior in this regard as well.
  • the Andrew Lipoplasty system described herein appears to be an ideal fat harvesting modality.
  • the supranatant that is collected using the Andrew approach may be centrifuged in a manner that is similar to the centrifuging process described above in the background section in connection with the Coleman approach.
  • the low density portion can be skimmed away and discarded and the remainder can be loaded into implantation syringes.
  • the high density portion can be drained off the bottom into implantation syringes.
  • the higher density portion which contains viable fat cells and is also rich in adipose progenitor cells (i.e., stem cells), can then be used for implantation into the subject.
  • the thermal and mechanical energy is just enough to achieve the desired effect on fat; the thermal energy is not high enough to liquefy non-fat tissue or to burn any tissue; and the mechanical energy not high enough to cut any tissue.
  • the temperature of the fluid is between 100 and 131°F
  • the pressure is between 600 and 1300 psi
  • the boluses contain between 20 and 50 microliters per pulse and are generated at between 30 and 50 pulses per second.
  • the temperature is 120° F
  • the pressure is 1100 psi
  • the boluses contain 25 microliters per pulse
  • the boluses are generated at about 40 pulses per second.
  • the energized saline stream may acts as a "selective proteolytic agent," causing proteolysis of some proteins but not others; (2) the energized saline stream may act as a "pseudo-protease”; and (3) the energized saline stream may causes a disabling of some of the adhesive glycoproteins located on the surface of adipose tissue cell membranes and in the extracellular matrix (ECM). These glycoproteins are disabled and the cells "unstick” from each other. The cells then disperse or disaggregate.
  • ECM extracellular matrix
  • Lipoaspirates from those anatomic sites were collected in 3 liter waste canisters and were allowed to gravity separate for about 20 to 30 minutes.
  • the lipoaspirates settled into a top portion containing fat tissue, called the supernatant, and into a bottom portion containing saline and a little blood, called the infranatant.
  • the top portion of the supernatant was found to be visibly different in appearance from the bottom portion, with the division being visibly demarcated at almost the exact mid point of the overall supernatant. In particular, the top half of the supernatant appeared "grainier" and less completely
  • the supernatant contained a plurality of layers, each of which had different properties.
  • hemacytometer grid cell counting slide and viewed under 40x magnification: a localized, tiny clump of adipocytes was observed, which appeared to have between 100 to 400 adipocytes. (Note that it is difficult to determine the precise number of adipocytes in a given clump because the clumps were a number of cell layers deep, and the depth is hard to see on a slide).
  • a total of 6 samples (two samples form each anatomic site) were obtained and viewed in this manner, and all six samples had similar clump sizes and appearance. The same process was done to the bottom half of the supernatant and it was found that the clump sizes were consistently smaller, with about half as many cells per clump (as compared to the clumps in the top half of the supernatant).
  • a clump size is on the order of 200 cells per clump is ideal. Since the clumps in the top half of the supernatant appeared to have between 100 to 400 adipocytes per clump, gravity settling may be used to separate the best portion of the lipoaspirate for subsequent implantation by simply waiting 20-30 minutes for the lipoaspirate to settle into a supernatant and an infranatant, and then using the top half of the supernatant as a source of fat cells that are well suited for subsequent reintroduction into another part of the patient's body. Alternatively, if fat cells arranged in smaller clumps are desired, the bottom half of the supernatant would be used instead. In this manner, the selection of a layer from within the gravity-settled supernatant provides selectivity for obtaining the desired clump size for a given use.
  • the fact that the Andrew supranatant is in a state of cell suspension also provides another major advantage: Since the supranatant automatically reaches a state of cellular suspension, it becomes possible to separate out the adipose progenitor cells (i.e., stem cells) from the rest of the fat using a centrifuge without using collagenase or other similar functioning enzymes or chemicals. Since adipose progenitor cells have the ability to differentiate into many different types of tissue, they can be very useful for many purposes.
  • adipose progenitor cells i.e., stem cells
  • One aspect of the invention relates to a method of harvesting fat tissue from a first anatomic location of a subject using a cannula that has an interior cavity and an orifice configured to permit fat tissue to enter the interior cavity.
  • This method includes generating a negative pressure in the interior cavity so that a portion of the fat tissue is drawn into the interior cavity via the orifice.
  • Fluid is delivered, via a conduit, so that the fluid exits the conduit within the interior cavity and impinges against the portion of the fat tissue that was drawn into the interior cavity.
  • the fluid is delivered at a pressure and temperature that causes the fat tissue to soften, liquefy, or gellify.
  • Matter is suctioned matter out of the interior cavity, and the matter includes at least some of the delivered fluid and at least some of the fat tissue that has been softened, liquefied, or gellified.
  • the matter that was suctioned away is collected and the operation of gravity, over time, separates the collected matter into (a) a supernatant that has a plurality of layers and (b) an infranatant.
  • Fat that is suitable for implantation in the subject is extracted from a particular layer selected from the plurality of layers.
  • the extracted fat is introduced into a second anatomic location of the subject.
  • the collected matter may be cooled.
  • the fluid is traveling in a substantially distal to proximal direction just before it impinges against the portion of the fat tissue that was drawn into the orifice.
  • the fluid is delivered in pulses at a temperature between 98° F and
  • the fluid is delivered at a pressure between 600 and 1300 psi, and more preferably between 900 and 1300 psi.
  • the matter is suctioned out of the interior cavity using a vacuum pressure between 300 and 700 mm Hg, and between 450 and 550 mm Hg may be a sweet spot within this range.
  • Another aspect of the invention relates to a method of harvesting fat tissue from a first anatomic location of a subject using a cannula that has an interior cavity and an orifice configured to permit fat tissue to enter the interior cavity.
  • This method includes generating a negative pressure in the interior cavity so that a portion of the fat tissue is drawn into the interior cavity via the orifice.
  • Fluid is delivered, via a conduit, so that the fluid exits the conduit within the interior cavity and impinges against the portion of the fat tissue that was drawn into the interior cavity.
  • the fluid is delivered at a pressure and temperature that causes the fat tissue to soften, liquefy, or gellify.
  • Matter is suctioned matter out of the interior cavity, and the matter includes at least some of the delivered fluid and at least some of the fat tissue that has been softened, liquefied, or gellified.
  • the matter that was suctioned away is collected and the operation of gravity, over time, separates the collected matter into (a) a supernatant that has a top half and a bottom half and (b) an infranatant. Fat that is suitable for implantation in the subject is extracted from the top half of the supernatant.
  • the extracted fat is introduced into a second anatomic location of the subject.
  • the collected matter may be cooled.
  • the fluid is traveling in a substantially distal to proximal direction just before it impinges against the portion of the fat tissue that was drawn into the orifice.
  • the fluid is delivered in pulses at a temperature between 98° F and
  • the fluid is delivered at a pressure between 600 and 1300 psi, and more preferably between 900 and 1300 psi.
  • the matter is suctioned out of the interior cavity using a vacuum pressure between 300 and 700 mm Hg, and between 450 and 550 mm Hg may be a sweet spot within this range.
  • Another aspect of the invention relates to a method of harvesting fat tissue from a first anatomic location of a subject using a cannula that has an interior cavity and an orifice configured to permit fat tissue to enter the interior cavity.
  • This method includes generating a negative pressure in the interior cavity so that a portion of the fat tissue is drawn into the interior cavity via the orifice. Fluid is delivered via a conduit, so that the fluid exits the conduit within the interior cavity and impinges against the portion of the fat tissue that was drawn into the interior cavity.
  • the fluid is delivered in pulses at a temperature between 98° F and 140° F and at a pressure between 600 and 1300 psi, and is traveling in a substantially distal to proximal direction just before it impinges against the portion of the fat tissue that was drawn into the orifice. At least some of the fat tissue that was drawn into the interior cavity is softened, liquefied, or gellified. Matter is suctioned out of the interior cavity, and the matter includes at least some of the delivered fluid and at least some of the fat tissue that has been softened, liquefied, or gellified.
  • the matter that was suctioned away is collected and the operation of gravity, over time, separates the collected matter into (a) a supernatant that has a top half and a bottom half and (b) an infranatant. Fat that is suitable for implantation in the subject is extracted from the top half of the supernatant.
  • the extracted fat is introduced into a second anatomic location of the subject.
  • the collected matter may be cooled.
  • the fluid is delivered at a temperature between 110° F and 140° F, and more preferably between 110° F and 120° F.
  • the fluid is delivered at a pressure between 900 and 1300 psi.
  • the matter is suctioned out of the interior cavity using a vacuum pressure between 300 and 700 mm Hg, and between 450 and 550 mm Hg may be a sweet spot within this range.
  • the embodiments described above may be used in various liposuction procedures including, without limitation, liposuction of the face, neck, jowls, eyelids, posterior neck (buffalo hump), back, shoulders, arms, triceps, biceps, forearms, hands, chest, breasts, abdomen, abdominal etching and sculpting, flanks, love handles, lower back, buttocks, banana roll, hips, saddle bags, anterior and posterior thighs, inner thighs, mons pubis, vulva, knees, calves, shin, pretibial area, ankles and feet. They may also be used in revisional liposuction surgery to precisely remove residual fatty tissues and firm scar tissue (areas of fibrosis) after previous liposuction.
  • the embodiments described above may also be used in conjunction with other plastic surgery procedures in which skin, fat, fascia and/or muscle flaps are elevated and/or removed as part of the surgical procedure.
  • This would include, but is not limited to facelift surgery (rhytidectomy) with neck sculpting and submental fat removal, jowl excision, and cheek fat manipulation, eyelid surgery (blepharoplasty), brow surgery, breast reduction, breast lift, breast augmentation, breast reconstruction, abdominoplasty, body contouring, body lifts, thigh lifts, buttock lifts, arm lifts (brachioplasty), as well as general reconstructive surgery of the head, neck, breast abdomen and extremities.
  • facelift surgery rhytidectomy
  • neck sculpting and submental fat removal jowl excision
  • cheek fat manipulation eyelid surgery (blepharoplasty)
  • brow surgery breast reduction, breast lift, breast augmentation, breast reconstruction, abdominoplasty, body contouring, body lifts, thigh lifts, buttock lifts,
  • the embodiments described above may be used in skin resurfacing of areas of the body with evidence of skin aging including but not limited to sun damage (actinic changes), wrinkle lines, smokers' lines, laugh lines, hyper pigmentation, melasma, acne scars, previous surgical scars, keratoses, as well as other skin proliferative disorders.
  • sun damage actinic changes
  • wrinkle lines wrinkle lines
  • smokers' lines laugh lines
  • hyper pigmentation melasma
  • acne scars previous surgical scars
  • keratoses as well as other skin proliferative disorders.
  • the embodiments described above may target additional tissue types including, without limitation, damaged skin with thickened outer layers of the skin (keratin) and thinning of the dermal components (collagen, elastin, hyaluronic acid) creating abnormal, aged skin.
  • the cannula would extract, remove, and target the damaged outer layers, leaving behind the healthy deep layers (a process similar to traditional dermabrasion, chemical peels (trichloroacetic acid, phenol, croton oil, salicyclic acid, etc.) and ablative laser resurfacing (carbon dioxide, erbium, etc.)
  • the heated stream would allow for deep tissue stimulation, lightening as well as collagen deposition creating tighter skin, with improvement of overall skin texture and/or skin tone with improvements in color variations. This process would offer increased precision with decreased collateral damage over traditional methods utilizing settings and delivery fluids which are selective to only the damaged target tissue.
  • Higher pressure settings may also be used for areas of hyperkeratosis, callus formation in the feet, hands knees, and elbows to soften, hydrate and moisturize excessively dry areas.
  • the cannula used in spinal nucleotomy procedures includes heated solution supply tubes within the cannula as described above.
  • the cannula further includes a flexible tip capable of moving in multiple axes, for example, up, down, right and left. Because of the flexible tip, a surgeon may insert a cannula through an opening in the annulus fibrosis and into the central area, where the nucleus pulpous tissue is located. The surgeon can then direct the cannula tip in any direction. Using the cannula in this manner the surgeon is able to clean out the nucleus pulpous tissue while leaving the annulus fibrosis and nerve tissue intact and unharmed.
  • the present design can be incorporated in to an endovascular catheter for removal of vascular thrombus and atheromatous plaque, including vulnerable plaque in the coronary arteries and other vasculature.
  • a cannula using the present design can be used in urologic applications that include, but are not limited to, trans -urethral prostatectomy and trans-urethral resection of bladder tumors.
  • the present design can be incorporated into a device or cannula used in endoscopic surgery.
  • An example of one such application is chondral or cartilage resurfacing in arthroscopic surgery.
  • the cannula can be used to remove irregular, damaged, or torn cartilage, scar tissue and other debris or deposits to generate a smoother articular surface.
  • Another example is in gynecologic surgery and the endoscopic removal of endometrial tissue in proximity to the ovary, fallopian tubes or in the peritoneal or retroperitoneal cavities.
  • the cannula can be modified to be used in the manner a bronchoscope is used; the inflamed lining of the bronchial tubes would be liquefied and aspirated, thereby allowing new, healthy bronchial tube tissue to take its place.
  • the various embodiments described each provide at least one of the following advantages: (1) differentiation between target tissue and non-target tissue; (2) clog resistance, since the liquid projected in a distal-to-proximal direction across the suction orifices, which generally prevents the suction orifice or the cannula from clogging or becoming obstructed; (3) a reduction in the level of suction compared to traditional liposuction, which mitigates damage to non-target tissue; (4) a significant reduction in the time of the procedure and the amount of cannula manipulation required; (5) a significant reduction in surgeon fatigue; (6) a reduction in blood loss to the patient; and (7) improved patient recovery time because there is less need for shearing of fatty tissue during the procedure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)

Abstract

Un tissu cible peut être prélevé chez un sujet au moyen d'une canule (30) comportant une cavité intérieure et un orifice (37) conçu pour permettre audit matériau de pénétrer dans ladite cavité. Cela est réalisé grâce à la génération d'une pression négative dans la cavité, cela ayant pour effet l'aspiration d'une partie du tissu par l'orifice. Un liquide est alors administré, par l'intermédiaire d'un conduit (35), de façon à ce que le liquide sorte du conduit au sein de la cavité et vienne en contact avec la partie du tissu aspirée par l'orifice. Le liquide arrive sous une pression et à température telles à entraîner le ramollissement, la liquéfaction ou la gélification du tissu. Le tissu ayant été ramolli, liquéfié ou gélifié est ensuite aspiré à l'extérieur. Le matériau ainsi aspiré à l'extérieur est recueilli et séparé par gravité, et la graisse pouvant être implantée chez le sujet est extraite d'une couche sélectionnée (par exemple correspondant à la moitié supérieure) du surnageant du matériau ainsi séparé par gravité.
PCT/US2012/056088 2011-09-20 2012-09-19 Recueil de tissus graisseux par liquéfaction tissulaire Ceased WO2013043703A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2849081A CA2849081A1 (fr) 2011-09-20 2012-09-19 Recueil de tissus graisseux par liquefaction tissulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536896P 2011-09-20 2011-09-20
US61/536,896 2011-09-20

Publications (1)

Publication Number Publication Date
WO2013043703A1 true WO2013043703A1 (fr) 2013-03-28

Family

ID=46982957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/056088 Ceased WO2013043703A1 (fr) 2011-09-20 2012-09-19 Recueil de tissus graisseux par liquéfaction tissulaire

Country Status (2)

Country Link
CA (1) CA2849081A1 (fr)
WO (1) WO2013043703A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4529942A3 (fr) * 2015-08-28 2025-06-18 Incuvate, LLC Système et procédé de surveillance d'aspiration

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167053A1 (en) * 2000-05-31 2003-09-04 Taufig Ahmmed Ziah Liposuction device
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050058632A1 (en) * 2001-12-07 2005-03-17 Hedrick Marc H. Cell carrier and cell carrier containment devices containing regenerative cells
US20080269722A1 (en) * 2007-04-30 2008-10-30 Andrew Mark S Liposuction based on tissue liquefaction
US20090192498A1 (en) * 2007-04-30 2009-07-30 Andrew Mark S Liposuction of visceral fat using tissue liquefaction
WO2012149371A2 (fr) * 2011-04-29 2012-11-01 Andrew Technologies Llc Récolte de tissu adipeux à l'aide de liquéfaction de tissu

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167053A1 (en) * 2000-05-31 2003-09-04 Taufig Ahmmed Ziah Liposuction device
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050058632A1 (en) * 2001-12-07 2005-03-17 Hedrick Marc H. Cell carrier and cell carrier containment devices containing regenerative cells
US20080269722A1 (en) * 2007-04-30 2008-10-30 Andrew Mark S Liposuction based on tissue liquefaction
US20090192498A1 (en) * 2007-04-30 2009-07-30 Andrew Mark S Liposuction of visceral fat using tissue liquefaction
WO2012149371A2 (fr) * 2011-04-29 2012-11-01 Andrew Technologies Llc Récolte de tissu adipeux à l'aide de liquéfaction de tissu

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4529942A3 (fr) * 2015-08-28 2025-06-18 Incuvate, LLC Système et procédé de surveillance d'aspiration

Also Published As

Publication number Publication date
CA2849081A1 (fr) 2013-03-28

Similar Documents

Publication Publication Date Title
US20120277698A1 (en) Harvesting fat tissue using tissue liquefaction
US9089361B2 (en) Liposuction based on tissue liquefaction
US20130261606A1 (en) Harvesting Fat Tissue Using Tissue Liquefaction
US8366700B2 (en) Liposuction of visceral fat using tissue liquefaction
US20240225688A1 (en) Atraumatically formed tissue compositions, devices and methods of preparation and treatment
AU2011255189A1 (en) Ultrasonic device for harvesting adipose tissue
US20140188039A1 (en) Liposuction of visceral fat using tissue liquefaction
WO2013043703A1 (fr) Recueil de tissus graisseux par liquéfaction tissulaire
US20240261491A1 (en) Devices for removal of visceral fat, and related systems and methods
CA2714428C (fr) Liposuccion de graisses viscerales utilisant une liquefaction de tissu
US12116596B2 (en) Method and apparatus for improved mesenchymal stem cell harvesting
US20230295579A1 (en) Method and apparatus for mesenchymal stem cells purification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12769563

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2849081

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12769563

Country of ref document: EP

Kind code of ref document: A1